A drug that boosts platelets may speed recovery after stem cell transplants in kids with thalassemia
NCT ID NCT07003269
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This observational study tests whether hetrombopag, a platelet-boosting drug, can safely speed platelet recovery in children with thalassemia who receive a half-matched (haploidentical) stem cell transplant. Thirty children aged 2 to 17 will be followed for 28 days after transplant to track how quickly their platelet counts rise and how many transfusions they need. The study also monitors for side effects like bleeding or blood clots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hetrombopag, a drug that stimulates platelet production, given as a shot after stem cell transplant
- What this could lead to
- If hetrombopag proves safe and effective, it could speed platelet recovery and reduce the need for platelet transfusions in children with thalassemia after a stem cell transplant.
- What could go wrong
- This is a small observational study with only 30 children, so results may not apply to everyone. The drug may cause side effects like bleeding or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THALASSEMIA IN CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Haikou, Hainan, 570208, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.